Pharma's Real-World Data Revolution
Pharmaceutical companies now have unprecedented access to vast and varied Real-World Data (RWD)
Turning this data into strategic assets is essential for driving innovation across the drug lifecycle, from discovery and development through market launch and ongoing patient care. As healthcare moves towards patient-centric and value-based models, harnessing RWD can accelerate launch timelines, improve brand positioning, and ultimately enhance patient outcomes and drive brand success .
Yet at the core of this untapped resource, lies a critical barrier. Suboptimal patient engagement, leading to medication non-adherence and poor health outcomes, can significantly hamper the commercial potential of RWD and pharmaceutical products. Digital health technologies offer partial solutions, but true engagement requires integrating digital and in-person strategies. How can pharma companies effectively hybridise these approaches to maximise RWD value and generate actionable Real-World Evidence (RWE)?
In partnership with Sciensus, this Financial Times webinar explored strategic approaches for harnessing RWD. Our panel of experts outlined how overcoming adherence and engagement challenges can unlock substantial competitive differentiation, streamline market access, and improve regulatory outcomes.
Hybrid Patient Engagement Models
How can pharma companies effectively adopt hybrid patient engagement models to address suboptimal medication adherence and improve patient outcomes?
Real-World Evidence and Regulatory Approvals
In what ways can actionable Real-World Evidence accelerate regulatory approvals, streamline market access negotiations, and improve reimbursement outcomes?
Analysing Patient Behaviours for Product Positioning
How are leading companies leveraging advanced analytics to uncover patterns in patient behaviours that drive targeted product positioning and differentiation?
We’re Here To Help
Upcoming Events
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice
